flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 Semaglutides Are Poised to Remake Chronic Kidney Disease Care Semaglutides Are Poised to Remake

The results suggest that the cardiovascular benefits of semaglutide could begin fairly early on

621 In patients with cryptogenic stroke and a history of thrombosis or rheumatological disease, it would seem reasonable to consider testing for antiphospholipid antibodies

Hormone imbalance, often caused by menopause, can lead to various symptoms and concerns that can significantly impact a persons quality of life

Trulicity is only indicated for diabetes

MGMT inhibition in ER positive breast cancer leads to CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1, ER and Survivin inhibition and enhances response to temozolomide

FDA guidance allows up to a year to demonstrate a 5% weight loss